Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.
Phase of Trial: Phase IV
Latest Information Update: 15 May 2018
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 08 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.